Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zedenoleucel - Marker Cell Therapy

Next Previous
Drug Profile

Zedenoleucel - Marker Cell Therapy

Alternative Names: Autologous cytotoxic T-cell therapeutic - Marker Cell Therapeutics; MT-401; MT-401-OTS; MultiTAA T cells Stage; MultiTAA T-cell therapy; MultiTAA-specific T cells; TAA-specific CTLs; Zelenoleucel

Latest Information Update: 10 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marker Therapeutics
  • Developer Baylor College of Medicine; Marker Cell Therapy
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer
  • Phase I/II Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma
  • Phase I Myelodysplastic syndromes
  • Discontinued Lymphoma; Ovarian cancer

Most Recent Events

  • 31 Jul 2026 Bayor College of Medicine completes a phase I trial in Lymphoma (Second-line therapy or greater) in USA (IV) (NCT01333046)
  • 30 Jun 2026 Baylor College of Medicine completes a phase-I clinical trials in Myelodysplastic syndromes and Acute myeloid leukaemia (In children, In adults, In the elderly, Second-line therapy or greater) in USA (IV) (NCT02494167)
  • 30 Oct 2025 Marker Therapeutics terminates the phase II ARTEMIS trial in Acute myeloid leukaemia (Adjuvant therapy, Second-line therapy or greater) in USA (IV, Infusion) due to the long vein-to-vein manufacturing timeline of MT 401 after 38 participants received the autologous MT 401 (NCT04511130)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top